Dr. David Thompson joins Mesentech SAB

Dr. Thompson is a former executive of Alexion where he was global leader of the asfotase alfa (Stensiq) program for the treatment of hypophosphatasia. Previously he was Executive Vice-President at Pfizer where he developed and commercialized lasofoxifene (Fablyn). Dr. Thompson started his career at Merck under the leadership of Gideon Rodan where he developed and commercialized Fosamax.